NMDA receptor antibody seropositivity in psychosis: A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP)

Kyle M. Blackburn; Elena I. Ivleva; Robert A. Weir; Mindy Kim; Steven C. Hopkins; Matthew E. Hudgens-Haney; Sarah K. Keedy; Elliot S. Gershon; John A. Sweeney; Matcheri S. Keshavan; Godfrey D. Pearlson; Brett A. Clementz; Carol A. Tamminga; Steven Vernino

doi:10.1016/j.schres.2020.01.004

NMDA receptor antibody seropositivity in psychosis: A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP)

Kyle M. Blackburn, Elena I. Ivleva, Robert A. Weir, Mindy Kim, Steven C. Hopkins, Matthew E. Hudgens-Haney, Sarah K. Keedy, Elliot S. Gershon, John A. Sweeney, Matcheri S. Keshavan, Godfrey D. Pearlson, Brett A. Clementz, Carol A. Tamminga, Steven Vernino

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	318-320
Number of pages	3
Journal	Schizophrenia Research
Volume	218
DOIs	https://doi.org/10.1016/j.schres.2020.01.004
State	Published - Apr 2020

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/j.schres.2020.01.004

Cite this

Blackburn, K. M., Ivleva, E. I., Weir, R. A., Kim, M., Hopkins, S. C., Hudgens-Haney, M. E., Keedy, S. K., Gershon, E. S., Sweeney, J. A., Keshavan, M. S., Pearlson, G. D., Clementz, B. A., Tamminga, C. A., & Vernino, S. (2020). NMDA receptor antibody seropositivity in psychosis: A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP). Schizophrenia Research, 218, 318-320. https://doi.org/10.1016/j.schres.2020.01.004

Blackburn, KM , Ivleva, EI, Weir, RA, Kim, M, Hopkins, SC, Hudgens-Haney, ME, Keedy, SK, Gershon, ES, Sweeney, JA, Keshavan, MS, Pearlson, GD, Clementz, BA, Tamminga, CA & Vernino, S 2020, 'NMDA receptor antibody seropositivity in psychosis: A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP)', Schizophrenia Research, vol. 218, pp. 318-320. https://doi.org/10.1016/j.schres.2020.01.004

@article{8c2d1e80d39a4399ae4d980246e859ab,

title = "NMDA receptor antibody seropositivity in psychosis: A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP)",

author = "Blackburn, {Kyle M.} and Ivleva, {Elena I.} and Weir, {Robert A.} and Mindy Kim and Hopkins, {Steven C.} and Hudgens-Haney, {Matthew E.} and Keedy, {Sarah K.} and Gershon, {Elliot S.} and Sweeney, {John A.} and Keshavan, {Matcheri S.} and Pearlson, {Godfrey D.} and Clementz, {Brett A.} and Tamminga, {Carol A.} and Steven Vernino",

note = "Funding Information: This work was supported in part by the National Institutes of Health ( MH077851 and MH103368 ). Funding Information: Dr. Tamminga reports the following financial disclosures: American Psychiatric Association, Deputy Editor; Astellas, Ad Hoc Consultant; Autifony, Ad Hoc Consultant; Intracellular Therapies (ITI), Advisory Board, drug development; Pfizer, Ad Hoc Consultant; Sunovion, Investigator Initiated grant funding. Investigator Initiated grant funding. The rest of the authors declare no conflict of interest. ",

year = "2020",

month = apr,

doi = "10.1016/j.schres.2020.01.004",

language = "English (US)",

volume = "218",

pages = "318--320",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

}

TY - JOUR

T1 - NMDA receptor antibody seropositivity in psychosis

T2 - A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP)

AU - Blackburn, Kyle M.

AU - Ivleva, Elena I.

AU - Weir, Robert A.

AU - Kim, Mindy

AU - Hopkins, Steven C.

AU - Hudgens-Haney, Matthew E.

AU - Keedy, Sarah K.

AU - Gershon, Elliot S.

AU - Sweeney, John A.

AU - Keshavan, Matcheri S.

AU - Pearlson, Godfrey D.

AU - Clementz, Brett A.

AU - Tamminga, Carol A.

AU - Vernino, Steven

N1 - Funding Information: This work was supported in part by the National Institutes of Health ( MH077851 and MH103368 ). Funding Information: Dr. Tamminga reports the following financial disclosures: American Psychiatric Association, Deputy Editor; Astellas, Ad Hoc Consultant; Autifony, Ad Hoc Consultant; Intracellular Therapies (ITI), Advisory Board, drug development; Pfizer, Ad Hoc Consultant; Sunovion, Investigator Initiated grant funding. Investigator Initiated grant funding. The rest of the authors declare no conflict of interest.

PY - 2020/4

Y1 - 2020/4

UR - http://www.scopus.com/inward/record.url?scp=85086525071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086525071&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2020.01.004

DO - 10.1016/j.schres.2020.01.004

M3 - Letter

C2 - 31952910

AN - SCOPUS:85086525071

SN - 0920-9964

VL - 218

SP - 318

EP - 320

JO - Schizophrenia Research

JF - Schizophrenia Research

ER -

NMDA receptor antibody seropositivity in psychosis: A pilot study from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this